【how much c4 for a garage door】Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?
Jazz Pharmaceuticals plc
JAZZ is how much c4 for a garage doorscheduled to report first-quarter 2017 results on May 9, after the market closes.
Jazz’s shares have significantly outperformed the Zacks classified Medical-Drugs industry so far this year. Specifically, the stock gained 46.4% during the period, while the industry recorded an increase of 5.3%.
Jazz has quite an encouraging earnings track record. Last quarter, the company comfortably surpassed expectations with a positive earnings surprise of 15.76%. In fact, the company beat estimates in all the last four quarters with an average positive earnings surprise of 25.34%.
Jazz Pharmaceuticals PLC Price and EPS Surprise
Jazz Pharmaceuticals PLC Price and EPS Surprise | Jazz Pharmaceuticals PLC Quote
Let’s see how things have shaped up for this quarter.
Factors at Play
At the first-quarter conference call, focus will be on the performance of Jazz’s lead product, Xyrem, for cataplexy and excessive daytime sleepiness (EDS). Investors will also be looking out for the company’s pipeline progress. Defitelio’s sales ramp-up in the U.S., patent litigations related to Xyrem and the company’s business development plans are also expected to draw attention.
Xyrem should deliver strong performance in the first quarter. The company is also striving to expand Xyrem’s label and is currently conducting a phase II/III EXPRESS study in children and adolescents who have cataplexy with narcolepsy. In Apr 2017, the company announced positive top-line efficacy results from the study.
Defitelio (veno-occlusive disease) was launched in the U.S. in early Apr 2016 and the sales drug have picked up pace. The company reported that 117 unique accounts ordered Defitileo in fourth-quarter 2016, with 71% reordering since its launch. At the fourth-quarter 2016 conference call, the company issued its guidance for Defitelio/defibrotide net sales for 2017 in the range of $130–$150 million. The company expects $45–$55 million sales in U.S. in 2017. Meanwhile, in Jan 2017 the company initiated a phase III clinical study on Defitelio for the potential prevention of veno-occlusive disease (VOD) in high-risk adult and pediatric patients.
However, Jazz has been facing challenges in building sufficient inventory levels for Erwinaze due to constrained manufacturing capacity. The company may continue to experience further supply disruptions in certain markets, including the U.S., in the first quarter and beyond.
On the other hand, in Apr 2017, the company announced positive efficacy results from a global multicenter, phase III TONES 2 study, in adult patients with excessive sleepiness associated with narcolepsy. In the study, JZP-110 demonstrated highly statistically significant improvement in the co-primary endpoints.
In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which it finished in early Apr 2017. We believe Vyxeos has multi-million dollar potential. We expect the company to update on Vyxeos at the first-quarter conference call.
Earnings Whispers
Our proven model does not conclusively show that Jazz will beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat estimates. Unfortunately, this is not the case here as you will see below.
Zacks ESP:
The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.32. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:
Jazz currently carries a Zacks Rank #4 (Sell). As it is, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Here are some health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Conatus Pharmaceuticals Inc. CNAT is scheduled to release results on May 4. The company has an Earnings ESP of +57.14% and a Zacks Rank #3. You can see
the complete list of today’s Zacks #1 Rank stocks here
.
ImmunoGen, Inc. IMGN is scheduled to release results on May 5. The company has an Earnings ESP of +8.33% and a Zacks Rank #3.
FIBROGEN INC FGEN is scheduled to release results on May 8. The company has an Earnings ESP of +23.81% and a Zacks Rank #3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
ImmunoGen, Inc. (IMGN): Free Stock Analysis Report
FibroGen, Inc (FGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
View comments
-
Post-Pandemic Retirement Planning Strategy Book Launches on June 1, 2020BRIEF-Bright Real Estate's Unit Wins Land Auction For 293.2 Million Yuan In Yunnan ProvinceBRIEF-Xiamen Kehua Hengsheng To Change Company Name To Kehua Hengsheng Co LtdHow Gun Safety Laws Have (And Haven’t) Changed Since Pulse & What Still Needs to Be DoneDo You Like HORNBACH Baumarkt AG (ETR:HBM) At This P/E Ratio?Illinois Tool Works: 4Q Earnings SnapshotAustralia central bank rates seen at record lows for two more years: Reuters pollWhat Kind Of Investor Owns Most Of Krakatoa Resources Limited (ASX:KTA)?Coupa Software, Inc. (COUP) Earnings Expected to Grow: Should You Buy?Fiat Chrysler CEO 2016 compensation was $12 million-filing
- ·ValOre Initiates Multi-faceted Optimization Testwork at Pedra Branca and Receives Preliminary Platsol™ Metallurgical Recoveries of 93.4% for Palladium and 95.3% for Platinum
- ·Camikaze, the First Drone to Capture Death-Defying Moments in All Its Glory
- ·BRIEF-Xinjiang Torch Gas Says Shareholders Plan To Unload A Combined 26.3 Percent Stake
- ·More Evidence Rolls In: Law Firms Boosted Revenues, Profits in 2018
- ·EU open to compensating firms hit by coronavirus, more help for Italy
- ·Malaysia's Dec palm oil exports up 1.8 pct -Amspec Malaysia
- ·Meet the New, Revamped Hollywood Foreign Press Association, 105 Members Strong
- ·BRIEF-Xiamen Kehua Hengsheng To Change Company Name To Kehua Hengsheng Co Ltd
- ·Pacific Empire Announces Engagement of OreQuest Consultants as Technical Advisors and the Sale of Shares of Nova Royalty Corp. for Proceeds of Approximately C$644,795
- ·Pay Up?, Clear as Mud, ‘Excellent’ Schools: The Morning Minute
- ·DLA Piper revenue grows 5% as firm cites knock-on effects of cyber attack
- ·China Stocks-Factors to watch on Wednesday
- ·To the millions of parents who didn’t choose to homeschool: This is a unique opportunity
- ·W.R. Berkley Corp. Appoints Philip Welt as GC, Executive VP
- ·AmerisourceBergen (ABC) Q1 2019 Earnings Conference Call Transcript
- ·Australia's Healthscope recommends Brookfield deal, shares surge
- ·Ferrari (RACE) Q3 Earnings Beat Estimates
- ·Kim Kardashian's Met Gala After Party Was a Slice of Pizza and a Hotel Room Photo Shoot
- ·Are Casta Diva Group S.p.A.’s (BIT:CDG) Interest Costs Too High?
- ·Is Schwab MarketTrack Growth Investor (SWHGX) a Strong Mutual Fund Pick Right Now?
- ·CANADA STOCKS-TSX plunges as coronavirus rout rages
- ·Fatalities on commercial passenger aircraft rise in 2018
- ·Malaysian palm producer FGV appoints new chief financial officer
- ·Wednesday Newspaper
- ·(APC) INVESTOR ALERT - Anadarko Petroleum Corporation - Bronstein, Gewirtz & Grossman, LLC Notifies Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: April 20, 2020
- ·What's My Credit Card CVV?
- ·Americans have a mix of concern and hope about the economy
- ·Why Tesla, MyoKardia, and Hologic Slumped Today
- ·Reasons to Hold Ultimate Software in Your Portfolio for Now
- ·Get Disruptive in 2019 With These 10 ETFs
- ·Bitcoin falls below 8,000 ahead of what is expected to be a rough day for U.S. stocks
- ·Famous People from Rhode Island: How many of these 50 famous people do you know?
- ·1st Capital Bank Announces Appointment of Phil Morreale as SVP, Managing Director in San Luis Obispo
- ·Do You Like nVent Electric plc (NYSE:NVT) At This P/E Ratio?
- ·Coronavirus strands merchant ship crews at sea for months
- ·Cardinal Health (CAH) Beats on Earnings & Revenues in Q4